|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
|
US7491805B2
(en)
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
US20050171040A1
(en)
*
|
2001-05-18 |
2005-08-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CEPT) gene expression using short interfering nucleic acid (siNA)
|
|
US7517864B2
(en)
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US20050261219A1
(en)
*
|
2001-05-18 |
2005-11-24 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
GB0212303D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Molecular targetting of IGF-1 receptor
|
|
GB0212302D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Method of selecting targets for gene silencing by RNA interference
|
|
DE60310944T3
(de)
|
2002-08-05 |
2017-08-03 |
Silence Therapeutics Gmbh |
Weitere neue formen von interferierende rns moleküle
|
|
AU2003261449A1
(en)
|
2002-08-07 |
2004-02-25 |
|
Compositions for rna interference and methods of use thereof
|
|
CA2881743A1
(en)
|
2002-09-25 |
2004-04-08 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
US9827263B2
(en)
|
2002-11-05 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
US7977471B2
(en)
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
|
US7691998B2
(en)
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
|
US7619081B2
(en)
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
|
US8163896B1
(en)
|
2002-11-14 |
2012-04-24 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US7612196B2
(en)
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
|
AU2003295600A1
(en)
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US7592442B2
(en)
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
|
US7635770B2
(en)
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
|
US7217807B2
(en)
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
|
WO2004063331A2
(en)
*
|
2003-01-03 |
2004-07-29 |
Gencia Corporation |
SiRNA MEDIATED POST-TRANSRIPTIONAL GENE SILENCING OF GENES INVOLVED IN ALOPECIA
|
|
EP1592412A1
(en)
*
|
2003-01-31 |
2005-11-09 |
Novartis AG |
Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
|
|
CA2518475C
(en)
|
2003-03-07 |
2014-12-23 |
Alnylam Pharmaceuticals, Inc. |
Irna agents comprising asymmetrical modifications
|
|
WO2004090108A2
(en)
*
|
2003-04-03 |
2004-10-21 |
Alnylam Pharmaceuticals |
Irna conjugates
|
|
ATE443765T1
(de)
|
2003-03-21 |
2009-10-15 |
Santaris Pharma As |
Analoga kurzer interferierender rna (sirna)
|
|
US7595379B2
(en)
|
2003-05-30 |
2009-09-29 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
|
US7541442B2
(en)
|
2003-05-30 |
2009-06-02 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
|
CA2526274C
(en)
|
2003-05-30 |
2015-12-01 |
Agensys, Inc. |
Prostate stem cell antigen (psca) variants and subsequences thereof
|
|
US7888497B2
(en)
|
2003-08-13 |
2011-02-15 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
US7294704B2
(en)
|
2003-08-15 |
2007-11-13 |
Diadexus, Inc. |
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
|
|
EP1660657A1
(en)
|
2003-08-28 |
2006-05-31 |
Novartis AG |
Interfering rna duplex having blunt-ends and 3'-modifications
|
|
WO2005044981A2
(en)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
|
US7476729B2
(en)
|
2003-10-24 |
2009-01-13 |
Institut Curie |
Dbait and uses thereof
|
|
EP1526177A1
(en)
|
2003-10-24 |
2005-04-27 |
Institut Curie |
Nucleic acids useful for triggering tumor cell lethality
|
|
US20050191653A1
(en)
*
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
|
US20070275918A1
(en)
*
|
2003-11-07 |
2007-11-29 |
The Board Of Trustees Of The University Of Illinois |
Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression
|
|
SE0303397D0
(sv)
*
|
2003-12-17 |
2003-12-17 |
Index Pharmaceuticals Ab |
Compounds and method for RNA interference
|
|
WO2005072057A2
(en)
|
2004-01-30 |
2005-08-11 |
Quark Biotech, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
|
WO2005078094A2
(en)
*
|
2004-02-06 |
2005-08-25 |
Dharmacon, Inc. |
Stabilized rnas as transfection controls and silencing reagents
|
|
ATE452188T1
(de)
|
2004-02-10 |
2010-01-15 |
Sirna Therapeutics Inc |
Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
|
|
ES2423060T3
(es)
*
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
|
US20080199438A1
(en)
*
|
2004-03-16 |
2008-08-21 |
Dnavec Research Inc. |
Methods For Suppressing Tumor Proliferation
|
|
CN1977044A
(zh)
*
|
2004-03-24 |
2007-06-06 |
肿瘤疗法科学股份有限公司 |
治疗胰腺癌的组合物和方法
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
EP2520652B1
(en)
|
2004-04-09 |
2015-06-10 |
Genecare Research Institute Co., Ltd |
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
|
|
EP1747022A4
(en)
|
2004-04-23 |
2010-03-31 |
Univ Columbia |
INHIBITION OF HAIRLESS PROTEIN MRNA
|
|
WO2006069782A2
(en)
|
2004-12-27 |
2006-07-06 |
Silence Therapeutics Ag. |
Lipid complexes coated with peg and their use
|
|
WO2005108572A1
(de)
*
|
2004-05-06 |
2005-11-17 |
Medizinische Hochschule Hannover |
Verbindungen und verfahren zur immunsuppression
|
|
US7605250B2
(en)
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
|
US7687616B1
(en)
|
2004-05-14 |
2010-03-30 |
Rosetta Genomics Ltd |
Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
|
|
JP5697297B2
(ja)
|
2004-05-14 |
2015-04-08 |
ロゼッタ ジノミクス リミテッド |
マイクロｎａｓおよびその使用
|
|
DE102004025881A1
(de)
|
2004-05-19 |
2006-01-05 |
Beiersdorf Ag |
Oligoribonukleotide zur Beeinflussung des Haarwachstums
|
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US7795419B2
(en)
|
2004-05-26 |
2010-09-14 |
Rosetta Genomics Ltd. |
Viral and viral associated miRNAs and uses thereof
|
|
EP2319925B1
(en)
|
2004-08-16 |
2018-07-25 |
Quark Pharmaceuticals, Inc. |
Therapeutic uses of inhibitors of RTP801
|
|
HUE033977T2
(en)
|
2004-08-23 |
2018-02-28 |
Sylentis Sau |
Treatment of eye disorders with siRNAs characterized by increased intraocular pressure
|
|
MX2007002423A
(es)
*
|
2004-08-31 |
2007-08-07 |
Sylentis Sau |
Metodos y composiciones para inhibir la expresion del receptor p2x7.
|
|
AU2005288522B2
(en)
|
2004-09-28 |
2012-06-28 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
|
|
WO2006039806A1
(en)
*
|
2004-10-14 |
2006-04-20 |
Institut De Cardiologie De Montreal |
Depression of herg k+ channel function in mammalian cells and applications to the control of cancer cells division
|
|
US20060253100A1
(en)
|
2004-10-22 |
2006-11-09 |
Medtronic, Inc. |
Systems and Methods to Treat Pain Locally
|
|
US7595159B2
(en)
|
2004-11-03 |
2009-09-29 |
The Brigham And Women's Hospital, Inc. |
Prediction of Parkinson's disease using gene expression levels of peripheral blood samples
|
|
KR100780548B1
(ko)
*
|
2004-12-08 |
2007-11-29 |
한국원자력연구원 |
Ｓ-아데노실 메티오닌 디카르복실라제 ｍＲＮＡ에특이적인 작은 간섭 ＲＮＡ 및 그를 유효성분으로포함하는 악성종양 치료제
|
|
AU2011203218B2
(en)
*
|
2004-12-09 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
|
US8003619B2
(en)
|
2004-12-09 |
2011-08-23 |
Alnylam Pharmaceuticals, Inc. |
Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide
|
|
EP2316942B1
(en)
*
|
2004-12-22 |
2021-04-21 |
Alnylam Pharmaceuticals, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
|
WO2006092714A2
(en)
*
|
2005-03-02 |
2006-09-08 |
National Institute Of Immunology |
Inhibition of spag9 expression with sirnas
|
|
GB0505081D0
(en)
|
2005-03-14 |
2005-04-20 |
Genomica Sau |
Downregulation of interleukin-12 expression by means of rnai technology
|
|
EP1873240B1
(en)
|
2005-04-15 |
2011-12-28 |
National University Corporation Tottori University |
hTERT GENE EXPRESSION REGULATORY GENE
|
|
KR20060119412A
(ko)
*
|
2005-05-20 |
2006-11-24 |
아주대학교산학협력단 |
ＩＬ-6 발현 억제를 위한 ｓｉＲＮＡ 및 이를 함유하는조성물
|
|
US20110125075A1
(en)
*
|
2005-07-15 |
2011-05-26 |
National University Corporation Nagoya University |
Method for control of electroporation apparatus
|
|
US7919583B2
(en)
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
|
BRPI0614407A2
(pt)
*
|
2005-08-17 |
2009-08-18 |
Sirna Therapeutics Inc |
molécula de ácido nucleico de filamento duplo, e, composição
|
|
GB0521351D0
(en)
|
2005-10-20 |
2005-11-30 |
Genomica Sau |
Modulation of TRPV expression levels
|
|
GB0521716D0
(en)
|
2005-10-25 |
2005-11-30 |
Genomica Sau |
Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
|
|
WO2007053803A2
(en)
*
|
2005-10-31 |
2007-05-10 |
Centocor, Inc. |
Antagonist of teb4 and methods of use
|
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
|
BRPI0620723A2
(pt)
*
|
2005-12-29 |
2011-11-22 |
Alcon Res Ltd |
inibição de igf1r mediada por rnai para tratamento de angiogênese ocular
|
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
NL2000439C2
(nl)
|
2006-01-20 |
2009-03-16 |
Quark Biotech |
Therapeutische toepassingen van inhibitoren van RTP801.
|
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
|
GB0605337D0
(en)
|
2006-03-17 |
2006-04-26 |
Genomica Sau |
Treatment of CNS conditions
|
|
WO2007107162A2
(en)
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
|
EP2007888A2
(en)
*
|
2006-04-03 |
2008-12-31 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
US8927704B2
(en)
|
2006-06-08 |
2015-01-06 |
Amino Up Chemical Co., Ltd |
Sense oligonucleotide capable of controlling the expression of iNOS and composition comprising the same
|
|
KR20090023464A
(ko)
|
2006-06-08 |
2009-03-04 |
가부시키가이샤 아미노 압 가가쿠 |
유전자 산물의 생산량을 제어하는 방법 및 생산량 제어제
|
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
WO2007141796A2
(en)
|
2006-06-09 |
2007-12-13 |
Quark Pharmaceuticals, Inc. |
Therapeutic uses of inhibitors of rtp801l
|
|
EP2061900A2
(en)
|
2006-08-25 |
2009-05-27 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
|
US20100034736A1
(en)
*
|
2006-09-07 |
2010-02-11 |
Consejo Superior De Investigaciones Cientificas |
Identification of cancer stem cells using genetic markers
|
|
CA2666657A1
(en)
*
|
2006-10-18 |
2008-04-24 |
Nastech Pharmaceutical Company Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のｓｉＲＮＡおよびその使用方法
|
|
EP2102360A2
(en)
|
2006-12-13 |
2009-09-23 |
Oncotherapy Science, Inc. |
Ttk as tumor marker and therapeutic target for lung cancer
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
US7872119B2
(en)
|
2007-02-26 |
2011-01-18 |
Quark Pharmaceuticals, Inc. |
Inhibitors of RTP801 and their use in disease treatment
|
|
WO2008109378A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting pdgfr gene expression and uses thereof
|
|
WO2008109492A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting igf1r gene expression and uses thereof
|
|
WO2008109359A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting pdgfr family gene expression and uses thereof
|
|
WO2008109454A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting fos gene expression and uses thereof
|
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
|
JP5296328B2
(ja)
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
１本鎖環状ｒｎａおよびその製造方法
|
|
WO2009001359A2
(en)
|
2007-06-27 |
2008-12-31 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of pro-apoptotic genes
|
|
WO2009021150A2
(en)
*
|
2007-08-08 |
2009-02-12 |
California Pacific Medical Center |
Platelet derived growth factor receptor supports cytomegalovirus infectivity
|
|
EP2187900B1
(en)
*
|
2007-08-16 |
2016-11-09 |
The Schepens Eye Research Institute, Inc. |
Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
|
|
WO2009028581A1
(en)
|
2007-08-24 |
2009-03-05 |
Oncotherapy Science, Inc. |
Cancer-related genes, cdca5, epha7, stk31 and wdhd1
|
|
CN101855346A
(zh)
|
2007-08-24 |
2010-10-06 |
肿瘤疗法科学股份有限公司 |
Pkib和naaladl2用作前列腺癌治疗和诊断的靶基因
|
|
EP2195428B1
(en)
|
2007-09-19 |
2013-12-11 |
Applied Biosystems, LLC |
SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF
|
|
EP2436376B1
(en)
|
2007-09-28 |
2014-07-09 |
BIND Therapeutics, Inc. |
Cancer cell targeting using nanoparticles
|
|
RU2487716C2
(ru)
*
|
2007-10-03 |
2013-07-20 |
Кварк Фармасьютикалс, Инк. |
Новые структуры малых интерферирующих рнк (sirna)
|
|
US20100317714A1
(en)
*
|
2007-11-29 |
2010-12-16 |
Suzhou Ribo Life Science Co., Ltd |
Complex molecule interfering the expression of target genes and its preparing methods
|
|
ES2535419T3
(es)
|
2007-12-27 |
2015-05-11 |
Protiva Biotherapeutics Inc. |
Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
|
|
EP2242504B1
(en)
*
|
2008-01-09 |
2021-07-14 |
The Schepens Eye Research Institute, Inc. |
Therapeutic compositions for treatment of ocular inflammatory disorders
|
|
JP5346957B2
(ja)
|
2008-01-23 |
2013-11-20 |
ヘルレフ ホスピタル |
不特定疾患の汎用マーカーとしてのｙｋｌ−４０
|
|
EP2264167B1
(en)
*
|
2008-03-31 |
2016-10-12 |
National Institute of Advanced Industrial Science and Technology |
Double-stranded lipid-modified rna having high rna interference effect
|
|
EP2285385A4
(en)
|
2008-04-15 |
2013-01-16 |
Quark Pharmaceuticals Inc |
COMPOUNDS BASED ON RNSI TO INHIBIT NRF2
|
|
EP2281041B1
(en)
|
2008-04-15 |
2014-07-02 |
Protiva Biotherapeutics Inc. |
Silencing of csn5 gene expression using interfering rna
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
USRE48948E1
(en)
|
2008-04-18 |
2022-03-01 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable polymer
|
|
WO2009131733A1
(en)
*
|
2008-04-21 |
2009-10-29 |
The Trustees Of Columbia University In The City Of New York |
Gab2 amplification in melanoma
|
|
WO2009147684A2
(en)
|
2008-06-06 |
2009-12-10 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treatment of ear disorders
|
|
WO2010008562A2
(en)
|
2008-07-16 |
2010-01-21 |
Recombinetics |
Methods and materials for producing transgenic animals
|
|
WO2010023877A1
(en)
|
2008-08-27 |
2010-03-04 |
Oncotherapy Science, Inc. |
Prmt1 for target genes of cancer therapy and diagnosis
|
|
WO2010028658A1
(en)
|
2008-09-15 |
2010-03-18 |
Herlev Hospital, Region Hovedstaden |
Ykl-40 as a marker for gastrointestinal cancers
|
|
JP2011251912A
(ja)
*
|
2008-09-22 |
2011-12-15 |
Gifu Prefecture Kenkyu Kaihatsu Zaidan |
マイクロｒｎａ―１４３誘導体を含有する医薬
|
|
US20100239632A1
(en)
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
|
WO2011019423A2
(en)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
|
US8951981B2
(en)
*
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
EP2475388B1
(en)
|
2009-09-10 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Use of il-33 antagonists to treat fibrotic disease
|
|
US9222086B2
(en)
|
2009-09-23 |
2015-12-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
AU2010324658A1
(en)
|
2009-11-26 |
2012-05-03 |
Quark Pharmaceuticals, Inc. |
siRNA compounds comprising terminal substitutions
|
|
EP2513308B1
(en)
|
2009-12-17 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Modulation of pilr to treat immune disorders
|
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
|
CN101787366B
(zh)
*
|
2010-03-04 |
2012-09-19 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
一种特异抑制Rab27B基因表达的DNA片段及其应用
|
|
MX2013000986A
(es)
|
2010-07-28 |
2013-07-03 |
Alcon Res Ltd |
Sirna dirigido al vegfa y metodos de tratamiento in vivo.
|
|
US9029341B2
(en)
|
2010-08-17 |
2015-05-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
|
US9243246B2
(en)
|
2010-08-24 |
2016-01-26 |
Sirna Therapeutics, Inc. |
Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
|
|
WO2012028703A1
(en)
*
|
2010-09-02 |
2012-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for the prognosis of the progression of cancer
|
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
JPWO2012063894A1
(ja)
|
2010-11-12 |
2014-05-12 |
国立大学法人愛媛大学 |
マイクロｒｎａのアンチセンスオリゴヌクレオチドを含む組成物
|
|
MX2013008833A
(es)
|
2011-02-02 |
2013-12-06 |
Amgen Inc |
Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
|
|
EP2723349A4
(en)
*
|
2011-06-27 |
2015-01-14 |
Medimmune Llc |
MICROARN-31 COMPOSITIONS AND METHODS OF USE IN AUTOIMMUNE DISEASES
|
|
EA024762B9
(ru)
|
2011-06-30 |
2017-04-28 |
Эрроухэд Рисерч Корпорейшн |
Композиции и способы ингибирования экспрессии генов вируса гепатита в
|
|
US10865383B2
(en)
|
2011-07-12 |
2020-12-15 |
Lineage Cell Therapeutics, Inc. |
Methods and formulations for orthopedic cell therapy
|
|
WO2013014073A1
(en)
|
2011-07-22 |
2013-01-31 |
Universite De Strasbourg |
Phospholipid-detergent conjugates and uses thereof
|
|
US9567585B2
(en)
*
|
2011-11-10 |
2017-02-14 |
Shire Human Genetic Therapies, Inc. |
Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
|
|
WO2013071056A2
(en)
|
2011-11-11 |
2013-05-16 |
Duke University |
Combination drug therapy for the treatment of solid tumors
|
|
SI3366775T2
(sl)
*
|
2011-11-18 |
2025-12-31 |
Alnylam Pharmaceuticals, Inc. |
Modificirana sredstva RNAI
|
|
EP2817287B1
(en)
|
2012-02-24 |
2018-10-03 |
Arbutus Biopharma Corporation |
Trialkyl cationic lipids and methods of use thereof
|
|
US11180760B2
(en)
*
|
2012-03-09 |
2021-11-23 |
The Johns Hopkins University |
Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
|
|
TWI480043B
(zh)
*
|
2012-05-01 |
2015-04-11 |
高雄醫學大學 |
用以治療塑化劑引發之雌激素受體陰性型乳癌的醫藥組成物
|
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
WO2013177194A1
(en)
*
|
2012-05-22 |
2013-11-28 |
University Of Massachusetts |
Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage
|
|
US20150322428A1
(en)
*
|
2012-06-18 |
2015-11-12 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for improved cellular uptake of antisense compounds
|
|
US8980259B2
(en)
|
2012-07-20 |
2015-03-17 |
Novartis Ag |
Combination therapy
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2700949A1
(en)
|
2012-08-24 |
2014-02-26 |
IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. |
Use of biliverdin reductase proteins as cancer marker
|
|
GB201215857D0
(en)
|
2012-09-05 |
2012-10-24 |
Sylentis Sau |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
AU2012389270B2
(en)
|
2012-09-05 |
2018-11-08 |
Sylentis S.A.U. |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
WO2014039648A2
(en)
*
|
2012-09-06 |
2014-03-13 |
Health Research, Inc. |
Compositions and methods for inhibiting hypoxia induced damage
|
|
US9944992B2
(en)
|
2013-03-15 |
2018-04-17 |
The University Of Chicago |
Methods and compositions related to T-cell activity
|
|
MX388221B
(es)
|
2013-04-20 |
2025-03-19 |
Res Institute At Nationwide Children´S Hospital |
ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2.
|
|
EP3888640B1
(en)
*
|
2013-06-05 |
2025-09-17 |
Reverse Bioengineering, Inc. |
Compositions and methods for induced tissue regeneration in mammalian species
|
|
CN105873568B
(zh)
|
2013-12-05 |
2019-10-08 |
赛伦斯治疗有限公司 |
用于肺特异性递送的工具
|
|
US11078462B2
(en)
|
2014-02-18 |
2021-08-03 |
ReCyte Therapeutics, Inc. |
Perivascular stromal cells from primate pluripotent stem cells
|
|
US10011837B2
(en)
|
2014-03-04 |
2018-07-03 |
Sylentis Sau |
SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
PL3145934T3
(pl)
|
2014-05-19 |
2021-08-16 |
Pfizer Inc. |
Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
US10240127B2
(en)
|
2014-07-03 |
2019-03-26 |
ReCyte Therapeutics, Inc. |
Exosomes from clonal progenitor cells
|
|
EP3172324A4
(en)
|
2014-07-18 |
2018-04-25 |
Oregon Health & Science University |
5'-triphosphate oligoribonucleotides
|
|
CA2957661A1
(en)
|
2014-08-09 |
2016-02-18 |
Kevin FLANIGAN |
Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
|
|
KR102545316B1
(ko)
|
2014-11-10 |
2023-06-22 |
알닐람 파마슈티칼스 인코포레이티드 |
Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
|
|
WO2016077620A1
(en)
|
2014-11-12 |
2016-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of hormonal disorders of growth
|
|
RU2563989C1
(ru)
*
|
2014-11-20 |
2015-09-27 |
Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) |
Композиция для подавления экспрессии гена цитокина интерлейкина-4
|
|
AU2016306275A1
(en)
|
2015-08-07 |
2018-02-08 |
Arrowhead Pharmaceuticals, Inc. |
RNAi therapy for Hepatitis B virus infection
|
|
CN108779435B
(zh)
|
2015-12-07 |
2022-05-03 |
再生疗法有限公司 |
用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
WO2017173297A1
(en)
|
2016-04-01 |
2017-10-05 |
Avidity Biosciences Llc |
Beta-catenin nucleic acids and uses thereof
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
WO2017173301A1
(en)
|
2016-04-01 |
2017-10-05 |
Avidity Biosciences Llc |
Egfr nucleic acids and uses thereof
|
|
EP3436585B1
(en)
|
2016-04-01 |
2022-07-20 |
Avidity Biosciences, Inc. |
Kras nucleic acids and uses thereof
|
|
AU2017264192B2
(en)
*
|
2016-05-10 |
2023-08-03 |
National University Corporation Tokyo Medical And Dental University |
Expression inhibitor of inflammation promoting factors, screening method for active ingredient thereof, expression cassette useful for said method, diagnostic agent and diagnosis method
|
|
US10036024B2
(en)
|
2016-06-03 |
2018-07-31 |
Purdue Research Foundation |
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
|
|
EP3269732A1
(en)
*
|
2016-07-11 |
2018-01-17 |
Rhemastem SRLS |
Therapeutic medium for the treatment of cancer
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
EP3315125A1
(en)
|
2016-10-31 |
2018-05-02 |
Silence Therapeutics (London) Ltd |
Lipid nanoparticle formulation
|
|
CA3043768A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11723912B2
(en)
|
2016-12-08 |
2023-08-15 |
University Of Utah Research Foundation |
Staufen1 agents and associated methods
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
CN110268060B
(zh)
|
2017-01-10 |
2024-07-26 |
箭头药业股份有限公司 |
α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法
|
|
US11324820B2
(en)
|
2017-04-18 |
2022-05-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
|
|
WO2018195250A1
(en)
*
|
2017-04-19 |
2018-10-25 |
Bio-Path Holdings, Inc. |
P-ethoxy nucleic acids for igf-1r inhibition
|
|
JP2020517645A
(ja)
|
2017-04-19 |
2020-06-18 |
バイオ−パス ホールディングス， インコーポレイテッド |
Ｉｇｆ−１ｒ阻害のためのｐ−エトキシ核酸
|
|
EP3638773A1
(en)
|
2017-06-16 |
2020-04-22 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Blood vessel organoid, methods of producing and using said organoids
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
KR102715821B1
(ko)
*
|
2017-11-09 |
2024-10-10 |
고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 |
암 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약, 및 진단 방법
|
|
AU2018378812B2
(en)
|
2017-12-06 |
2025-05-22 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
|
WO2019168897A2
(en)
*
|
2018-02-28 |
2019-09-06 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
|
|
EP3765516A2
(en)
*
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3807291A4
(en)
|
2018-06-14 |
2022-02-23 |
University of Utah Research Foundation |
STAUFEN1 REGULATORY AGENTS AND ASSOCIATED PROCEDURES
|
|
CN108977445B
(zh)
*
|
2018-06-29 |
2021-05-25 |
山东农业大学 |
拟南芥microRNA400在调控植物耐镉性中的应用
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
US10857174B2
(en)
|
2018-07-27 |
2020-12-08 |
United States Government As Represented By The Department Of Veterans Affairs |
Morpholino oligonucleotides useful in cancer treatment
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3108282A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP3833397A4
(en)
*
|
2018-08-08 |
2023-06-14 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
|
|
JP7625512B2
(ja)
|
2018-08-13 |
2025-02-03 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
|
|
KR102097794B1
(ko)
*
|
2018-09-17 |
2020-04-06 |
차의과학대학교 산학협력단 |
신규한 miRNA smR-167 및 폐암 예방 또는 치료를 위한 이의 용도
|
|
WO2020117715A1
(en)
|
2018-12-03 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Oligo-benzamide analogs and their use in cancer treatment
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
WO2020219820A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
WO2020225779A1
(en)
|
2019-05-09 |
2020-11-12 |
Istituto Pasteur Italia - Fondazione Cenci Bolognetti |
Rig-i agonists for cancer treatment and immunotherapy
|
|
MX2021015003A
(es)
|
2019-06-06 |
2022-01-24 |
Arrowhead Pharmaceuticals Inc |
Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
|
|
EP4121018A4
(en)
|
2020-03-17 |
2024-07-03 |
Genevant Sciences Gmbh |
CATIONIC LIPIDS FOR LIPID DNANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLA CELLS
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
SI4126066T1
(sl)
|
2020-03-27 |
2026-04-30 |
Avidity Biosciences, Inc. |
Sestavki in postopki zdravljenja mišične distrofije
|
|
WO2021252799A2
(en)
*
|
2020-06-11 |
2021-12-16 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing msh3 expression
|
|
IL299826A
(en)
|
2020-07-15 |
2023-03-01 |
Cerebral Therapeutics Inc |
A medical device with a non-filtered CSF withdrawal path
|
|
EP4225917A1
(en)
*
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
|
DE102020128677A1
(de)
*
|
2020-10-30 |
2022-05-05 |
Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Körperschaft des öffentlichen Rechts |
Ein neues Target zur Behandlung der Nierenfibrose
|
|
AU2021403156A1
(en)
|
2020-12-18 |
2023-07-13 |
Genevant Sciences Gmbh |
Peg lipids and lipid nanoparticles
|
|
AU2022212580A1
(en)
*
|
2021-01-30 |
2023-07-27 |
E-Therapeutics Plc |
Nucleic acids containing abasic nucleotides
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
CN118265544A
(zh)
|
2021-09-16 |
2024-06-28 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|
|
IL312811A
(en)
|
2021-11-16 |
2024-07-01 |
Shanghai Argo Biopharmaceutical Co Ltd |
Composition and method for inhibiting angiotensinogen (agt) protein expression
|
|
CN118900701A
(zh)
|
2022-01-31 |
2024-11-05 |
盖纳万科学有限公司 |
聚(烷基噁唑啉)-脂质缀合物及含有聚(烷基噁唑啉)-脂质缀合物的脂质颗粒
|
|
KR20240146674A
(ko)
|
2022-01-31 |
2024-10-08 |
제네반트 사이언시즈 게엠베하 |
지질 나노입자를 위한 이온화 가능한 양이온성 지질
|
|
US12605537B2
(en)
|
2022-02-15 |
2026-04-21 |
Biogen Ma Inc. |
Implantable medical device for use with or having recording electrode
|
|
AU2023245603A1
(en)
|
2022-03-28 |
2024-11-07 |
Empirico Inc. |
Modified oligonucleotides
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
WO2024159113A1
(en)
*
|
2023-01-27 |
2024-08-02 |
The Methodist Hospital |
Modulators of alternative polyadenylation and methods of use thereof
|
|
WO2024215814A2
(en)
*
|
2023-04-10 |
2024-10-17 |
Anand Rene |
Methods and pharmaceutical compositions for treating aging
|
|
WO2025052278A1
(en)
|
2023-09-05 |
2025-03-13 |
Genevant Sciences Gmbh |
Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|
|
WO2026083241A1
(en)
|
2024-10-15 |
2026-04-23 |
Genevant Sciences Gmbh |
Ionizable lipids comprising n,n-substituted hydroxylamine esters
|